Metrics to compare | SHRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSHRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.9x | −0.8x | −0.4x | |
PEG Ratio | 0.58 | −0.44 | 0.00 | |
Price/Book | −14.0x | 3.3x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.1x | |
Upside (Analyst Target) | - | 148.5% | 57.4% | |
Fair Value Upside | Unlock | 31.3% | 7.7% | Unlock |
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.